1. Antiproliferative effect of 1α,25-dihydroxyvitamin D3 involves upregulation of cyclin-dependent kinase inhibitor p21 in human pancreatic cancer cells.
- Author
-
Kanemaru M, Maehara N, and Chijiiwa K
- Subjects
- Aged, Blotting, Western, Cell Line, Tumor, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms mortality, Pancreatic Neoplasms pathology, Receptors, Calcitriol genetics, Up-Regulation drug effects, Calcitriol pharmacology, Cell Proliferation drug effects, Cyclin-Dependent Kinase Inhibitor p21 analysis, Pancreatic Neoplasms drug therapy
- Abstract
Background/aims: The aim of this study was to investigate the effect of 1α,25-dihydroxyvitamin D3 on proliferation of human pancreatic cancer cell lines and to identify related cell cycle regulatory proteins with antiproliferative effects., Methodology: Human pancreatic cancer cell lines SUIT-2 and its four sublines, and Panc-1, AsPC-1, and MiaPaCa-2 were treated with1α,25-dihydroxyvitamin D3. The number of cells was measured by the MTT method, and the cell cycle regulatory proteins were then analyzed by Western blotting., Results: Eight human pancreatic cancer cell lines expressed vitamin D receptor (VDR) mRNA. 1α,25-dihydroxyvitamin D3 inhibited proliferation of SUIT-2 and its sublines. We found p21 to be upregulated after 24 hours in S2-028, the cell line in which proliferation was most inhibited by 1α,25-dihydroxyvitamin D3., Conclusions: 1α,25-dihydroxyvitamin D3 inhibited proliferation of pancreatic cancer cells and is involved in the upregulation of cyclin-dependent kinase inhibitor p21.
- Published
- 2013
- Full Text
- View/download PDF